• Even if NP 32101 is eventually dropped for atopic dermatitis, it is still possible that the drug will be useful in gastrointestinal disorders.

    FORBES: Nucryst's Nano Silver Lining

  • Investors need to think a bit longer-term here and realize that even if the atopic dermatitis route turns out to be a dead end, the future of Nucryst is still looking bright.

    FORBES: Nucryst's Nano Silver Lining

  • "Nucryst is continuing to analyze data from this study so that we can evaluate options for our atopic dermatitis program with a complete understanding of the study results, " says President and CEO Scott H.

    FORBES: Nucryst's Nano Silver Lining

  • "The stock is oversold, and as the dust settles, the third-quarter earnings will be coming out with cash flow and revenues from Acticoat, and people will value the stock based on that, and probably on the assumption that atopic dermatitis is not going to come back, " says Wolff.

    FORBES: Nucryst's Nano Silver Lining

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定